Surgery and proton radiation therapy for pediatric base of skull chordomas: Long-term clinical outcomes for 204 patients
Neuro-Oncology · 2023
DOI: 10.1093/neuonc/noad068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Myrsini Ioakeim-Ioannidou und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Chordoma, Skull Base Neoplasms, Chondrosarcoma, Proton Therapy. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: American Radium Society, American Society for Radiation Oncology, Harvard Medical School.
Abstract (Originalsprache)
Background
Data on clinical outcomes for base of skull (BOS) chordomas in the pediatric population is limited. We report patient outcomes after surgery and proton radiotherapy (PRT).
Methods
Pediatric patients with BOS chordomas were treated with PRT or combined proton/photon approach (proton-based; for most, 80% proton/20% photon) at the Massachusetts General Hospital from 1981 to 2021. Endpoints of interest were overall survival (OS), disease-specific survival, progression-free survival (PFS), freedom from local recurrence (LC), and freedom from distant failure (DC).
Results
Of 204 patients, median age at diagnosis was 11.1 years (range, 1–21). Chordoma location included 59% upper and/or middle clivus, 36% lower clivus, 4% craniocervical junction, and 1% nasal cavity. Fifteen (7%) received pre-RT chemotherapy. Forty-seven (23%) received PRT, and 157 (77%) received comboRT. Median total dose was 76.7 Gy (RBE) (range, 59.3–83.3). At a median follow-up of 10 years (interquartile range, 5–16 years), 56 recurred. Median OS and PFS were 26 and 25 years, with 5-, 10-, and 20-year OS and PFS rates of 84% and 74%, 78% and 69%, and 64% and 64%, respectively. Multivariable actuarial analyses showed poorly differentiated subtype, radiographical progression prior to RT, larger treatment volume, and lower clivus location to be prognostic factors for worse OS, PFS, and LC. RT was well tolerated at a median follow-up of 9 years (interquartile range, 4–16 years). Side effects included 166 patients (80%) with mild/moderate acute toxicities, 24 (12%) patients with late toxicities, and 4 (2%) who developed secondary radiation-related malignancies.
Conclusion
This is the largest cohort of BOS chordomas in the literature, pediatric and/or adult. High-dose PRT following surgical resection is effective with low rates of late toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Department of Radiotherapy, School of Medicine, University of Crete, Heraklion, Greece.
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
- Department of Pediatric Hematology-Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Yin P Hung
Förderung
- American Radium Society
- American Society for Radiation Oncology
- Harvard Medical School
Zitieren
APA
Ioakeim-Ioannidou, M., Niemierko, A., Kim, D. W., Tejada, A., Urell, T., Leahy, S., Adams, J., Fullerton, B., Nielsen, G. P., Hung, Y. P., Shih, A. R., Patino, M., Buch, K., Rincon, S., Kelly, H., Cunnane, M. B., Tolia, M., Widemann, B. C., Wedekind, M. F., …, & MacDonald, S. M. (2023). Surgery and proton radiation therapy for pediatric base of skull chordomas: Long-term clinical outcomes for 204 patients. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad068
Vancouver
Ioakeim-Ioannidou M, Niemierko A, Kim DW, Tejada A, Urell T, Leahy S, et al. Surgery and proton radiation therapy for pediatric base of skull chordomas: Long-term clinical outcomes for 204 patients. Neuro-Oncology. 2023. doi:10.1093/neuonc/noad068
BibTeX
@article{IoakeimIoannidou2023,
author = {Ioakeim-Ioannidou, Myrsini and Niemierko, Andrzej and Kim, Daniel W and Tejada, Athena and Urell, Tobias and Leahy, Shannon and Adams, Judy and Fullerton, Barbara and Nielsen, G Petur and Hung, Yin P and Shih, Angela R and Patino, Manuel and Buch, Karen and Rincon, Sandra and Kelly, Hilary and Cunnane, Mary Beth and Tolia, Maria and Widemann, Brigitte C and Wedekind, Mary F and John, Liny and Ebb, David and Shin, John H and Cote, Gregory and Curry, William and MacDonald, Shannon M},
title = {Surgery and proton radiation therapy for pediatric base of skull chordomas: Long-term clinical outcomes for 204 patients},
journal = {Neuro-Oncology},
year = {2023},
doi = {10.1093/neuonc/noad068}
}
EUVIMED